Maternal-fetal infections, also known as congenital infections, occur when pathogens such as cytomegalovirus (CMV), toxoplasmosis, syphilis, HIV, or Zika virus are transmitted from mother to fetus during pregnancy or delivery. These infections can cause miscarriage, stillbirth, developmental delays, and lifelong health complications in newborns. Early screening, vaccination, prenatal care, and appropriate treatments are critical to reducing risks and improving maternal and neonatal outcomes. Public health initiatives increasingly focus on awareness, preventive care, and integrated management strategies to minimize transmission.
Market Analysis: In 2025, the global market for maternal-fetal infection diagnostics, therapeutics, and preventive care is valued at around USD 3.9 billion. With growing emphasis on prenatal screening, advanced molecular diagnostics, and maternal vaccination programs, the market is expected to reach approximately USD 6.4 billion by 2030, at a CAGR of 10.4%. North America and Europe dominate due to high adoption of advanced prenatal care, while Asia-Pacific is emerging as the fastest-growing region, driven by rising birth rates and government investments in maternal health.
